Moderna (NASDAQ:MRNA) Given New $45.00 Price Target at JPMorgan Chase & Co.

Moderna (NASDAQ:MRNA - Free Report) had its target price trimmed by JPMorgan Chase & Co. from $59.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has an underweight rating on the stock.

MRNA has been the topic of a number of other reports. Leerink Partners dropped their price objective on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a research report on Tuesday, September 17th. The Goldman Sachs Group lowered their target price on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a report on Monday, September 16th. Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They issued an "underperform" rating and a $40.00 target price for the company. Oppenheimer cut shares of Moderna from an "outperform" rating to a "market perform" rating in a report on Friday, September 13th. Finally, Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $83.26.

Moderna Stock Down 3.7 %

MRNA traded down $1.61 during trading hours on Tuesday, hitting $42.05. 7,245,018 shares of the company's stock were exchanged, compared to its average volume of 4,897,437. Moderna has a 12-month low of $35.80 and a 12-month high of $170.47. The firm has a 50 day moving average of $54.45 and a 200 day moving average of $93.15. The firm has a market cap of $16.18 billion, a P/E ratio of -7.45 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm earned ($1.39) EPS. The firm's revenue for the quarter was up 3.8% on a year-over-year basis. Analysts predict that Moderna will post -9.44 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 2,930 shares of company stock worth $217,170. Company insiders own 15.20% of the company's stock.

Hedge Funds Weigh In On Moderna

A number of large investors have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC purchased a new position in Moderna during the 2nd quarter valued at about $26,000. Family Firm Inc. purchased a new position in Moderna during the 2nd quarter valued at about $33,000. Bank & Trust Co purchased a new position in Moderna during the 2nd quarter valued at about $36,000. Hanseatic Management Services Inc. purchased a new position in Moderna during the 2nd quarter valued at about $48,000. Finally, Plato Investment Management Ltd increased its holdings in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock valued at $49,000 after acquiring an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.